CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer



Summary

CD160, a surface receptor on CD8+ T cells, plays a crucial role in resistance to anti-PD-1 immunotherapy in colorectal cancer (CRC). Research demonstrates that high CD160 expression on CD8+ T cells promotes T cell exhaustion, rendering them less effective at killing tumor cells despite PD-1 blockade. Mechanistically, CD160 exacerbates the exhausted phenotype, reducing the efficacy of anti-PD-1 therapy. Therefore, targeting CD160, perhaps in combination with anti-PD-1, could potentially reinvigorate exhausted CD8+ T cells and overcome immunotherapy resistance in CRC, improving patient outcomes.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!